You are here

Focus on increased low adherence in any oral cancer treatment

Interview with Andrea Antonuzzo, MD, recorded at ESMO, September 2014.

Interview with Andrea Antonuzzo, MD, recorded at ESMO, September 2014.

Adherence is a big problem in oral cancer therapy because low adherence leads to low efficacy, bad outcomes and bad quality of life. Dr. Andrea Antonuzzo sketches the reasons for bad adherence and what can be done to improve it. Further topics: the differences between patient care in clinical studies and the real-world clinical practice and why there is a need for trials with unselected patients and for more prospective studies with Quality of Life evaluation for new drugs, due to an increasing number of fast drug approvals where the toxicities are not very well known.

 

Andrea Antonuzzo, MD, is Head of Supportive Care Unit, Medical Oncology 1, at Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

Search this site

Featured videos

Free access to ebooks on cachexia and CINV

 

Prevention of nausea and vomiting in
adult cancer patients receiving tumour-
directed therapy – 2017 update –

and
Cancer cachexia: mechanisms and progress in treatment

 

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo

Share